Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ribavirin

FDA-approved product (for solution, inhalation), marketed as Copegus, Rebetol, Ribasphere and 2 more.

Registered studies
50+
Lab records
2
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Ribavirin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Cirrhosis of liver
  • Fibrosis
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
FDA pharmacologic class
Nucleoside Analog Antiviral FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP01; FDA class Nucleoside Analog Antiviral

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Ribavirin, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA19.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli5.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae5.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis22.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 0 of 1 lab record
Open Ribavirin in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ribavirin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of CKD Patients With HCV

    NCT07770984 · start 2026-09-15

    Registered record
    Registry ID
    NCT07770984
    Conditions
    HCV Infection ( Genotype 4) in CKD Patients
    Interventions
    SOF+DCV; OBV/PTV/r) ± ribavirin (RBV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09-15
    Completion
    2027-05-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV Infection ( Genotype 4) in CKD Patients
    InterventionSOF+DCV; OBV/PTV/r) ± ribavirin (RBV)
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • New Antiviral Drugs for Treatment of COVID-19

    NCT04392427 · start 2020-10

    Registered record
    Registry ID
    NCT04392427
    Conditions
    COVID; Drug Effect
    Interventions
    Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-10
    Completion
    2022-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID; Drug Effect
    InterventionTreatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
    PhasePhase 3
    Registry statusUnknown

  • Cardiovascular Function and Ribavirin PK/PD in Lassa Fever in Lassa Fever

    NCT04285034 · start 2019-11-26

    Registered record
    Registry ID
    NCT04285034
    Conditions
    Lassa Fever
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-11-26
    Completion
    2021-07-15
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLassa Fever
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Effect Of DAAs For Treatment Of HCV On Normal Kidney

    NCT03296930 · start 2017-10-01

    Registered record
    Registry ID
    NCT03296930
    Conditions
    Antiviral Drug Adverse Reaction
    Interventions
    Sofosbuvir 400 MG Oral Tablet,; Ombitasvir/paritaprevir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-10-01
    Completion
    2018-10-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiviral Drug Adverse Reaction
    InterventionSofosbuvir 400 MG Oral Tablet,; Ombitasvir/paritaprevir/ritonavir
    PhasePhase 4
    Registry statusUnknown

  • Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

    NCT02890719 · start 2016-08-03

    Registered record
    Registry ID
    NCT02890719
    Conditions
    Liver Transplantation; Hepatitis C
    Interventions
    Grazoprevir 100 mg/day; Elbasvir 50 mg/d; Grazoprevir 100 mg/day; Elbasvir 50 mg/day; Ribavirin 1200 mg/day
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2016-08-03
    Completion
    2017-06-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation; Hepatitis C
    InterventionGrazoprevir 100 mg/day; Elbasvir 50 mg/d; Grazoprevir 100 mg/day; Elbasvir 50 mg/day +1 more
    PhasePhase 3
    Registry statusWithdrawn

  • Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

    NCT03488485 · start 2016-06-18

    Registered record
    Registry ID
    NCT03488485
    Conditions
    Chronic Hepatitis c
    Interventions
    Direct Acting Antivirals
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-06-18
    Completion
    2020-12
    Enrolment
    50,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis c
    InterventionDirect Acting Antivirals
    PhaseNot applicable
    Registry statusUnknown

  • An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection

    NCT02597270 · start 2016-03

    Registered record
    Registry ID
    NCT02597270
    Conditions
    Hepatitis C Virus
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-11
    Enrolment
    239

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Directly Observed Therapy for HCV in Chennai, India

    NCT02541409 · start 2015-09

    Registered record
    Registry ID
    NCT02541409
    Conditions
    Hepatitis C, Chronic
    Interventions
    Sofosbuvir; Pegylated Interferon alfa-2a; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-09
    Completion
    2016-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionSofosbuvir; Pegylated Interferon alfa-2a; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4

    NCT02371408 · start 2015-01

    Registered record
    Registry ID
    NCT02371408
    Conditions
    Chronic Hepatitis C
    Interventions
    ravidasvir hydrochloride; sofosbuvir; ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2016-04
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    Interventionravidasvir hydrochloride; sofosbuvir; ribavirin
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

    NCT02175758 · start 2014-07-07

    Registered record
    Registry ID
    NCT02175758
    Conditions
    Hepatitis C Virus Infection
    Interventions
    SOF; RBV
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-07-07
    Completion
    2018-09-13
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus Infection
    InterventionSOF; RBV
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

    NCT02128542 · start 2014-06

    Registered record
    Registry ID
    NCT02128542
    Conditions
    Hepatitis C Virus Infection
    Interventions
    Sofosbuvir; RBV
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-06
    Completion
    2015-06
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus Infection
    InterventionSofosbuvir; RBV
    PhasePhase 4
    Registry statusCompleted

  • A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin.

    NCT02150291 · start 2014-05

    Registered record
    Registry ID
    NCT02150291
    Conditions
    Hepatitis C
    Interventions
    Folic acid; Neurobion; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2014-05
    Completion
    2015-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionFolic acid; Neurobion; placebo
    PhasePhase 4
    Registry statusUnknown

  • A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

    NCT02068222 · start 2014-04

    Registered record
    Registry ID
    NCT02068222
    Conditions
    Chronic Hepatitis C; Hepatitis C Virus
    Interventions
    ABT-450/ritonavir (r); ABT-530; Ribavirin (RBV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04
    Completion
    2015-03
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C; Hepatitis C Virus
    InterventionABT-450/ritonavir (r); ABT-530; Ribavirin (RBV)
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection

    NCT02021643 · start 2013-12-10

    Registered record
    Registry ID
    NCT02021643
    Conditions
    Chronic HCV Infection
    Interventions
    Sofosbuvir; RBV; PEG
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12-10
    Completion
    2016-11-03
    Enrolment
    687

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic HCV Infection
    InterventionSofosbuvir; RBV; PEG
    PhasePhase 3
    Registry statusCompleted

  • Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

    NCT02107365 · start 2013-11

    Registered record
    Registry ID
    NCT02107365
    Conditions
    Hepatitis C Virus Genotype 4 Infection
    Interventions
    Asunaprevir; Daclatasvir; Ribavirin; Pegylated Interferon alpha-2a
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-11
    Completion
    2015-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus Genotype 4 Infection
    InterventionAsunaprevir; Daclatasvir; Ribavirin; Pegylated Interferon alpha-2a
    PhasePhase 2
    Registry statusCompleted